IRadimed (IRMD) Q1 2025 earnings summary

Executive summary

• Achieved record Q1 2025 revenue of $19.5 million, up 11% year-over-year, marking the fifteenth consecutive quarter of record revenues.

• Net income rose to $4.7 million ($0.37 per diluted share), up 16% from Q1 2024; non-GAAP net income was $5.3 million ($0.42 per diluted share), up 17%.

• Gross profit margin remained steady at 76.1% year-over-year.

• U.S. sales grew 19% to $16 million, now 82% of total revenue, while international sales declined 15% to $3.5 million.

• Continued leadership in MRI-compatible medical devices, with ongoing product innovation and expansion.

Financial highlights

• Revenue increased to $19.5 million from $17.6 million in Q1 2024, driven by 16% growth in IV infusion pump systems and 23% growth in disposables.

• Operating income was $5.4 million, up 14% year-over-year, with a 28% operating margin.

• Cash and cash equivalents were $50.3 million as of March 31, 2025; working capital was $66.7 million.

• Cash flow from operations was $4.3 million, up 10% from Q1 2024; free cash flow was $0.4 million, with $3.9 million in capital expenditures for a new facility.

• Stockholders' equity rose to $90.1 million; total assets were $101.7 million as of March 31, 2025.

Outlook and guidance

• Q2 2025 revenue expected at $19.7–$19.9 million; GAAP diluted EPS $0.37–$0.40, non-GAAP $0.41–$0.44.

• Full-year 2025 revenue guidance reiterated at $78–$82 million; GAAP diluted EPS $1.55–$1.65, non-GAAP $1.71–$1.81.

• New 3870 MRI IV pump expected to contribute light revenue in Q4 2025, with significant impact in 2026 and beyond.

• Management expects higher revenue and operating expenses for the remainder of 2025, driven by increased device and accessory sales and higher sales, marketing, and regulatory costs.

• Current cash and operations are expected to meet requirements for at least the next 12 months.